• 1. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450
• 2. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 3. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 4. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 5. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Amino fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Amino fatty acids

Recent Advances in the Study of (3R)-3-amino-5-methoxy-5-oxopentanoic acid (CAS: 77856-50-9)

In recent years, (3R)-3-amino-5-methoxy-5-oxopentanoic acid (CAS: 77856-50-9) has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, a chiral amino acid derivative, has shown promising potential in various therapeutic applications, including enzyme inhibition, metabolic pathway modulation, and drug delivery systems. The latest studies have focused on its synthesis, biological activity, and potential clinical applications, making it a subject of intense scientific inquiry.

One of the key areas of research involves the optimization of synthetic routes for (3R)-3-amino-5-methoxy-5-oxopentanoic acid. Recent publications highlight novel enzymatic and chemical methods that improve yield and enantiomeric purity, which are critical for its pharmaceutical applications. For instance, a 2023 study demonstrated the use of immobilized lipases in asymmetric synthesis, achieving over 95% enantiomeric excess (ee) under mild conditions. This advancement addresses previous challenges in scalability and cost-effectiveness, paving the way for industrial production.

The biological activity of (3R)-3-amino-5-methoxy-5-oxopentanoic acid has also been a focal point. Researchers have identified its role as a precursor in the biosynthesis of gamma-aminobutyric acid (GABA) analogs, which are relevant in neurological disorders. In vitro and in vivo studies have shown that this compound exhibits moderate inhibitory effects on glutamate decarboxylase, suggesting potential applications in epilepsy and anxiety disorders. Furthermore, its metabolic stability and low toxicity profile make it a viable candidate for further preclinical development.

Another exciting development is the exploration of (3R)-3-amino-5-methoxy-5-oxopentanoic acid in drug delivery systems. Due to its unique physicochemical properties, such as high water solubility and biocompatibility, it has been incorporated into prodrug designs. A recent patent application describes its conjugation with anticancer agents, enhancing their bioavailability and reducing systemic toxicity. This innovation could revolutionize targeted therapy, particularly in oncology.

In conclusion, the latest research on (3R)-3-amino-5-methoxy-5-oxopentanoic acid (CAS: 77856-50-9) underscores its multifaceted potential in chemical biology and pharmaceuticals. From improved synthetic methodologies to novel therapeutic applications, this compound continues to inspire innovation. Future studies are expected to delve deeper into its mechanistic pathways and clinical translation, solidifying its position as a valuable asset in drug discovery and development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)